MUC16 and neoplasm: It is believed (but not proven) that MUC16 undergoes cleavage in the penultimate SEA domain to generate circulating CA125 [24], which is well known for its application as a clinical biomarker for the diagnosis of tumor recurrence, especially for EOC.